Biosimilars: Where we were and where we are

Journal of Biopharmaceutical Statistics

Volumn 24, Issue 6, 2014, Pages 1154-1164

  Challand, Rodeina ^a   Gorham, Hazel ^a   Constant, John ^a  

^a PRA HEALTH SCIENCES   (United States)

Author keywords

Biosimilars; Regulatory framework; Statistical design

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT;

ARTICLE; COMPETITION; DRUG LEGISLATION; DRUG SURVEILLANCE PROGRAM; EUROPEAN UNION; HUMAN; PRACTICE GUIDELINE; STUDY DESIGN; DRUG APPROVAL; DRUG DEVELOPMENT; ECONOMICS; GOVERNMENT REGULATION; LEGISLATION AND JURISPRUDENCE; PHARMACEUTICS; STANDARDS; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES;

BIOPHARMACEUTICS; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUG DISCOVERY; EUROPEAN UNION; GOVERNMENT REGULATION; UNITED STATES;

EID: 84910071803     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2014.941994     Document Type: Article

References (26)

1. Brazilian Health Surveillance Agency. (2010). Resolution no. 55/2010, Brazil.
2. Chow, S. C. (2013a). Assessing biosimilarity and drug interchangeability of biosimilar products. Statistics in Medicine 32:361-363.
3. Chow, S. C. (2013b). Biosimilars: Design and Analysis of Follow-on Biologics. New York, NY: Chapman & Hall/CRC Press, Taylor & Francis Group.
4. Committee for Medicinal Products for Human Use. (2013). Draft Guideline on Similar Biological Medicinal Products, 22 May 2013, CHMP/437/04 Rev 1 2.
5. European Commission. (2001). Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use (as amended by directive 2003/63/EC and Directive 2004/27/EC).
6. European Commission. (2012). Directive 2012/26/EU of the European Parliament and of the Council, 25 October 2012 amending Directive 2001/83/EC as regards pharmacovigilance; Regulation (EU) no 1027/2012 of the European Parliament and of the Council, 25 October 2012 amending Regulation (EC) No 726/2004 as regards pharmacovigilance.
7. European Medicines Agency. (2009). Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins, 19 March 2009, EMEA/CHMP/BMWP/118264/2007.
8. European Medicines Agency. (2010). Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision), 18 March 2010, EMEA/CHMP/BMWP/301636/2008.
9. European Medicines Agency. (2012a). Guideline on similar biological medicinal products containing monoclonal antibodies - Non-clinical and clinical issues, 30 May 2012, EMA/CHMP/BMWP/403543/2010.
10. European Medicines Agency. (2012b). Draft guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues (revision 1), 24 May 2012, EMA/CHMP/BWP/247713/2012.
11. European Medicines Agency. (2013a). Draft guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues, 03 June May 2013, EMEA/CHMP/BMWP/42832/2005 Rev. 1.
12. European Medicines Agency. (2013b). Draft Guideline on non-clinical and clinical development of similar biological medicinal products containing low molecular-weight-heparins, 17 January 2013, EMEA/CHMP/BMWP/118264/2007 Rev. 1
13. European Medicines Agency. (2013c). Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development. EMA/297149/2013.
14. McBride, B. (2013). EU regulators give landmark backing to Remicade biosimilars. Fierce Biotech, June 28.
15. Food and Drug Administration. (2012a). Scientific considerations in demonstrating biosimilarity to a reference product, FDA draft guidance, February.
16. Food and Drug Administration. (2012b). Quality considerations in demonstrating biosimilarity to a reference protein product, FDA draft guidance, Feb 2012
17. Food and Drug Administration. (2012c). Biosimilars: Questions and answers regarding Implementation of the Biologics Price Competition and Innovation Act of 2009, FDA draft guidance, February.
18. Food and Drug Administration. (2013). Guidance for Industry Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants, FDA draft guidance, March. GaBI Online. n.d.-a. Generics and biosimilars initiative. Naming requirements in Australian biosimilars guidance [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International [accessed October 8, 2013).
19. GaBI Online. n.d.-b. Generics and biosimilars initiative. Fight continues over biosimilar naming standards [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International (accessed October 17, 2013).
20. Health Canada. (2010). Guidance for sponsors: Information and submission requirements for subsequent entry biologics (SEBs). Health Canada, Ottawa, Canada. Patient Protection and Affordable Care Act (amended by the Health Care and Education Reconciliation Act) (P.L. 111-1148). (2010). United States, March 23, 2010.
21. Title VII. (2010). Biologics Price Competition & Innovation Act (BPCIA), United States. March.
22. Tsoua, H-H., Changa, W.-J., Hwanga, W.-S., and Laia, Y.-H. (2013). A consistency approach for evaluation of biosimilar products. Journal of Biopharmaceutical Statistics 23(5):1054-1066.
23. World Health Association. (2009). Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Geneva, Switzerland: WHO.
24. World Health Organization. (2013a). WHO executive summary. 55th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 16-18 October 2012. INN Working Doc. 13.329. February.
25. World Health Organization. (2013b). WHO executive summary. 56th Consultation on International Nonproprietary Names for Pharmaceutical Substances Geneva, 15-17 April 2013. INN Working Doc. 13.335. September.
26. Zhang, N., et al (2013). Impact of variability on the choice of biosimilarity limits in assessing followon biologics. Statistics in Medicine 32:424-433.